"paper"

As part of the EU-funded EBRAINS 2.0 project, we are excited to announce a special issue in the European Journal of Neurology, inviting researchers to contribute original studies that explore the intersection of neuroscience, digital innovation, and its clinical applications.

For February we have selected two co-papers of the month, each of which examines the safety and efficacy of a specific drug in the treatment of patients with generalised myasthenia gravis.

A new paper published in Nature Reviews Neurology offers a cogent overview of patient involvement in medicine in the context of public participation in democratic processes.

A new EAN paper published in the European Journal of Neurology presents a roadmap toward reducing the burden imposed on patients, caregivers, and society by neurological diseases in Europe.

Our paper of the month compares drug prescription prior to the clinical onset of sporadic Creutzfeldt-Jakob disease in patients versus matched controls aiming to uncover potential risk or protective factors.

Our paper of the month highlights the findings of the stage 2 interim analysis from the first cycle of MND SMART, a phase 3, multi-arm, randomised, adaptive platform trial conducted across 20 centres in the UK.

Our paper of the month for November presents the findings from two large trials comparing the safety and efficacy of evobrutinib with teriflunomide in adults with a diagnosis of relapsing MS.

Our Paper of the Month for October is a phase 2, double-blind, randomised, placebo-controlled trial investigating the efficacy of a monoclonal antibody (Lu AG09222) that inhibits PACAP signalling.

The EAN strongly endorses the newly published EBC perspective paper on Rethinking Alzheimer's Disease given that Alzheimer's disease is a devastating neurological disease affecting more and more people in Europe and across the world due to ageing societies.

Our paper of the month for September updates the 2020 Lancet Commission report on the identification of risk factors for dementia, adding two more risk factors to the list.

Our paper of the month for August is a randomised controlled trial evaluating tenecteplase administered 4.5 to 24 hours after stroke onset in 516 Chinese patients.

Our paper of the month is an observational cohort study exploring the link between sleep measures and AD pathology in 319 participants (mean ± SD age: 61.5 ± 5.4 years; 47% female) from the Rotterdam Study, a prospective population-based study conducted in the Netherlands.

Our paper of the month reports the result of a trial investigating the safety and the potential efficacy of intravenous treatment with acyl-ghrelin in improving neurological outcome in patients in a coma after cardiac arrest.

In our Paper of the Month for May, researchers traced the trajectory of Alzheimers biomarkers, for the first time employing a longitudinal design, with impressive, groundbreaking results.

Our paper of the month for April is the latest work by the Global Burden of Diseases Collaborator Network, which has found that neurological conditions are the leading cause of ill health and disability worldwide, with over 3.4 billion people worldwide are affected.